We are live on ! Find out more
RA

Rosalind Advisors Portfolio holdings

AUM $249M
1-Year Est. Return 80.12%
This Fund
S&P 500
This Quarter Est. Return
+19.75%
1 Year Est. Return
+80.12%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$156M
AUM Growth
+$26.2M
Cap. Flow
+$107M
Cap. Flow %
68.62%
Top 10 Hldgs %
70.44%
Holding
44
New
5
Increased
13
Reduced
10
Closed
11

Top Buys

Rank Stock Value
1
CRMD icon
CorMedix
CRMD
+$7.98M
2
HELP
Cybin Inc
HELP
+$5.61M
3
CLRB icon
Cellectar Biosciences
CLRB
+$2.12M
4
MDWD icon
MediWound
MDWD
+$2.09M
5
MYO icon
Myomo
MYO
+$1.48M

Top Sells

Rank Stock Value
1
VRDN icon
Viridian Therapeutics
VRDN
+$3.9M
2
ABVX
Abivax
ABVX
+$2.86M
3
CLSD
Clearside Biomedical
CLSD
+$2.81M
4
TRVI icon
Trevi Therapeutics
TRVI
+$1.91M
5
RZLT icon
Rezolute
RZLT
+$1.07M

Sector Composition

Rank Sector Weight
1 Healthcare 96.49%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
DCTH icon
1
Delcath Systems
DCTH
$416M
$21.2M 13.57%
2,650,389
– –
MYO icon
2
Myomo
MYO
$38.6M
$12.1M 7.76%
3,021,391
+356,392
+13% +$1.48M
CRMD icon
3
CorMedix
CRMD
$588M
$11.9M 7.63%
+1,475,000
New +$7.98M
ABEO icon
4
Abeona Therapeutics
ABEO
$369M
$11.6M 7.41%
1,832,000
+82,000
+5% +$428K
MDWD icon
5
MediWound
MDWD
$181M
$11.3M 7.26%
628,050
+114,560
+22% +$2.09M
HELP
6
Cybin Inc
HELP
$505M
$9.56M 6.12%
1,075,105
+567,210
+112% +$5.61M
XERS icon
7
Xeris Biopharma Holdings
XERS
$1.45B
$8.85M 5.67%
3,104,995
-15,175
-0.5% -$39K
VRNA
8
DELISTED
Verona Pharma
VRNA
$7.91M 5.07%
275,000
+25,000
+10% +$615K
CLRB icon
9
Cellectar Biosciences
CLRB
$20.2M
$7.86M 5.03%
122,385
+32,198
+36% +$2.12M
OCUL icon
10
Ocular Therapeutix
OCUL
$1.85B
$7.7M 4.93%
885,000
+135,000
+18% +$1.11M
NSPR icon
11
InspireMD
NSPR
$31.5M
$6.74M 4.31%
2,514,046
+405
+0% +$1.1K
OPTN
12
DELISTED
OptiNose
OPTN
$5.55M 3.55%
552,500
+49,357
+10% +$720K
CMPS
13
Compass Pathways
CMPS
$1.56B
$4.92M 3.15%
781,423
+47,423
+6% +$335K
PROF
14
Profound Medical
PROF
$263M
$3.87M 2.48%
485,973
-47,360
-9% -$428K
CRMD icon
15
CALL
CorMedix
CRMD
$588M
$3.64M 2.33%
+700,000
New +$3.79M
KALV
16
DELISTED
KalVista Pharmaceuticals
KALV
$3.52M 2.25%
303,864
-34,121
-10% -$429K
TRVI icon
17
Trevi Therapeutics
TRVI
$2.61B
$2.5M 1.6%
750,000
-641,577
-46% -$1.91M
OTLK icon
18
Outlook Therapeutics
OTLK
$194M
$2.4M 1.54%
450,000
– –
PYPD icon
19
PolyPid
PYPD
$83.8M
$2.34M 1.5%
679,168
+262,368
+63% +$943K
VERU icon
20
Veru
VERU
$35.6M
$2.07M 1.33%
269,450
-150
-0.1% -$1.29K
ABVX
21
Abivax
ABVX
$10.8B
$1.61M 1.03%
139,983
-238,433
-63% -$2.86M
FLNA
22
PUT
Filana Therapeutics
FLNA
$46.4M
$1.45M 0.93%
367,400
+363,727
+9,903% +$8.38M
OWLT icon
23
Owlet
OWLT
$153M
$1.21M 0.78%
+270,000
New +$1.18M
KPRX icon
24
Kiora Pharmaceuticals
KPRX
$11.3M
$935K 0.6%
255,555
– –
FBIO icon
25
Fortress Biotech
FBIO
$109M
$727K 0.47%
502,828
-104,969
-17% -$200K
1
2

Similar funds

TAM
Tabor Asset Management New York $249M AUM 48.59% 1-Year Est. Return
SCM
Step Capital Management Singapore $249M AUM
FDDB
Fidelity D&D Bancorp Dunmore, Pennsylvania $249M AUM 18.9% 1-Year Est. Return
MC
Mount Capital London, United Kingdom $248M AUM 4.81% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
GWS
Greykasell Wealth Strategies Danville, California $248M AUM 22.08% 1-Year Est. Return
SCM
Segra Capital Management Palm Beach, Florida $248M AUM 65.61% 1-Year Est. Return
ER
EVR Research Richmond, Virginia $250M AUM 41.5% 1-Year Est. Return

Rosalind Advisors's Q3 2024 Portfolio in Review

As of Q3 2024, Rosalind Advisors held 44 positions worth $156M, up 20% from $130M the previous quarter. Its ten largest holdings account for 70% of the portfolio.

Rosalind Advisors deployed $107M of net new capital in Q3 2024, opening 5 new positions and adding to 13 existing holdings. Its largest new stake was CorMedix: 1,475,000 shares worth $11.9M.

By sector, the portfolio is most concentrated in Healthcare at 96% of assets, down from 97% a quarter earlier.

On the sell side, the largest reduction was Abivax, an estimated $2.86M trimmed.

  • Rosalind Advisors's largest Q3 2024 buy was CorMedix: 1,475,000 shares worth $11.9M.
  • Rosalind Advisors added most to Cybin Inc in Q3 2024, an estimated $5.61M increase.
  • Rosalind Advisors's biggest Q3 2024 reduction was Abivax, cutting an estimated $2.86M.
  • Rosalind Advisors fully exited Viridian Therapeutics in Q3 2024, selling an estimated $3.9M.
  • Rosalind Advisors's ten largest holdings make up 70% of its $156M portfolio in Q3 2024.
  • Rosalind Advisors opened 5 new positions and closed 11 in Q3 2024.
  • Rosalind Advisors's portfolio value rose 20% quarter-over-quarter to $156M.

Based on Rosalind Advisors's 13F filing for Q3 2024, filed 30 Oct 2024.